Acorda Therapeutics(ACOR) - 2023 Q4 - Annual Report

ldeFutue pr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3831168 (State or other jurisdict ...